Nowadays, ovarian cancer and breast cancer are two conditions for which PARP is prescribed. The applicability of PARP inhibitors is currently being expanded, nevertheless, according to researchers. For instance, the University Of Michigan Rogel Cancer Center prepared to conduct Phase II trials of the investigational medication combination of olaparib and AZD6738 in December 2018 for the management of metastatic castration-resistant prostate cancer. Additionally, a product's marketing may be delayed as a result of regulatory approval delays, which may have an impact on the manufacturer's income. Similar to this, a delay in the drug's post-approval for other therapeutic indications drives up the expense of clinical trials and may have an effect on the labelling and approval status of already-on-the-market goods. Therefore, these factors are anticipated to restrain the growth of the PARP inhibitor market.
The global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market was valued at US$ 887.7 Mn in 2018, and is expected to exhibit a CAGR of 32.4% over the forecast period (2019–2027).
Prominent Companies in the PARP Inhibitor Industry:
1. AstraZeneca plc
AstraZeneca PLC was incorporated in 1992.The company is headquartered in Cambridge, the United Kingdom and operational in more than 100 countries. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. In December, 2022 AstraZeneca’s Calquence (acalabrutinib), a selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naïve chronic lymphocytic leukaemia (CLL)
2. Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. On October 2022, The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's therapy for treating a type of multiple myeloma, the company said on Tuesday, giving another treatment option to patients with the incurable blood cancer.
3. GlaxoSmithKline PLC
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. On May 2020, it was reported that GSK tap experimental arthritis antibody to calm cytokine storm hitting COVID-19 patients.
4. Pfizer Inc.
Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sell biopharmaceutical products worldwide. In December, 2022 announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age.
5. AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide since 2012. It is headquartered in North Chicago and operational in more than 70 countries. AbbVie and HotSpot Therapeutics, Inc., in December, 2022 announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases.
6. Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products globally from 1887. The company was headquartered in New York, New York. In September, 2022 announced that the U.S. Food and Drug Administration (FDA) approved Sotyktu™ (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Sotyktu is not recommended for use in combination with other potent immunosuppressants.
7. Merck KGaA
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. In January, 2023 Merck completes acquisition of the chemical business of Mecaro.
8. Clovis Oncology Inc.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado.
9. Genentech, Inc.
Founded in 1976, Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients. The company has headquarters in South San Francisco, California.
10. Repare Therapeutics Inc.,
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
*Definition - Inhibitors of Poly ADP-Ribose Polymerase (PARP) are lengthy chains that contain 17 enzymes that link together multiple ADP-ribose units into a chain and transmit them to the target proteins.
